Skip to main content

Compare Stocks

Date Range: 

 Travere TherapeuticsAurinia PharmaceuticalsHarmony BiosciencesArcutis BiotherapeuticsImmunoGen
SymbolNASDAQ:TVTXNASDAQ:AUPHNASDAQ:HRMYNASDAQ:ARQTNASDAQ:IMGN
Price Information
Current Price$18.90$10.96$26.10$25.55$6.40
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.81.41.61.5
Analysis Score3.53.53.53.53.3
Community Score2.83.02.12.22.4
Dividend Score0.00.00.00.00.0
Ownership Score0.02.50.81.71.7
Earnings & Valuation Score0.00.00.60.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$42.67$28.00$51.67$54.67$10.10
% Upside from Price Target125.75% upside155.47% upside97.96% upside113.96% upside57.81% upside
Trade Information
Market Cap$1.14 billion$1.40 billion$1.48 billion$1.28 billion$1.28 billion
Beta0.770.87N/AN/A1.65
Average Volume584,2644,484,916132,757264,9832,229,170
Sales & Book Value
Annual Revenue$175.34 million$320,000.00N/AN/A$82.27 million
Price / Sales6.524,388.14N/AN/A15.55
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.15 per share$2.45 per shareN/AN/A($0.51) per share
Price / Book3.674.47N/AN/A-12.55
Profitability
Net Income$-146,430,000.00$-123,850,000.00N/A$-42,000,000.00$-104,130,000.00
EPS($3.46)($0.89)N/A($22.78)($0.70)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/A22.50N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-40.24%-173,992.23%N/AN/A-77.65%
Return on Equity (ROE)-29.27%-36.98%N/A-81.74%N/A
Return on Assets (ROA)-12.25%-31.06%N/A-57.72%-26.98%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.71%N/A2.04%N/AN/A
Current Ratio6.60%17.23%7.87%9.18%2.20%
Quick Ratio6.50%16.95%7.80%9.18%2.20%
Ownership Information
Institutional Ownership PercentageN/A51.21%50.17%79.63%72.95%
Insider Ownership Percentage4.63%N/AN/AN/A3.77%
Miscellaneous
EmployeesN/A2941505479
Shares Outstanding60.46 million128.12 million56.89 million50.21 million199.94 million
Next Earnings Date7/29/2021 (Estimated)8/10/2021 (Estimated)8/10/2021 (Estimated)8/10/2021 (Estimated)7/30/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
COVID-19 mRNA vaccines are immunogenic in pregnant and lactating women - EurekAlertCOVID-19 mRNA vaccines are immunogenic in pregnant and lactating women - EurekAlert
eurekalert.org - May 13 at 1:40 PM
Brokers Offer Predictions for ImmunoGen, Inc.s Q2 2021 Earnings (NASDAQ:IMGN)Brokers Offer Predictions for ImmunoGen, Inc.'s Q2 2021 Earnings (NASDAQ:IMGN)
americanbankingnews.com - May 13 at 8:58 AM
Q2 2021 Earnings Forecast for ImmunoGen, Inc. Issued By Piper Sandler (NASDAQ:IMGN)Q2 2021 Earnings Forecast for ImmunoGen, Inc. Issued By Piper Sandler (NASDAQ:IMGN)
americanbankingnews.com - May 13 at 8:58 AM
SVB Leerink Weighs in on ImmunoGen, Inc.s Q2 2021 Earnings (NASDAQ:IMGN)SVB Leerink Weighs in on ImmunoGen, Inc.'s Q2 2021 Earnings (NASDAQ:IMGN)
americanbankingnews.com - May 13 at 8:58 AM
Leerink Partners Stick to Their Hold Rating for Immunogen By Investing.com - Investing.comLeerink Partners Stick to Their Hold Rating for Immunogen By Investing.com - Investing.com
investing.com - May 13 at 8:40 AM
Global Antibody-drug Conjugates Market 2021 to 2026 Flourishing Analysis Done By Major Players: ImmunoGen, Seattle Genetics, Roche, Takeda – The Manomet Current - The Manomet CurrentGlobal Antibody-drug Conjugates Market 2021 to 2026 Flourishing Analysis Done By Major Players: ImmunoGen, Seattle Genetics, Roche, Takeda – The Manomet Current - The Manomet Current
manometcurrent.com - May 12 at 1:13 PM
ImmunoGen (NASDAQ:IMGN) Rating Reiterated by William BlairImmunoGen (NASDAQ:IMGN) Rating Reiterated by William Blair
americanbankingnews.com - May 12 at 7:06 AM
ImmunoGen (NASDAQ:IMGN) Receives "Outperform" Rating from William BlairImmunoGen (NASDAQ:IMGN) Receives "Outperform" Rating from William Blair
marketbeat.com - May 12 at 6:28 AM
ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 11 at 3:28 PM
ImmunoGen Stock Over 25% Down In The Last 14 Days - Via News AgencyImmunoGen Stock Over 25% Down In The Last 14 Days - Via News Agency
via.news - May 11 at 10:15 AM
HC Wainwright Stick to Their Buy Rating for Immunogen By Investing.com - Investing.comHC Wainwright Stick to Their Buy Rating for Immunogen By Investing.com - Investing.com
investing.com - May 11 at 10:15 AM
ImmunoGen Stock Bearish By 23% In The Last 14 Days - Via News AgencyImmunoGen Stock Bearish By 23% In The Last 14 Days - Via News Agency
via.news - May 10 at 8:07 PM
ImmunoGen Stock Is 9% Down As Session Comes To An End Today - Via News AgencyImmunoGen Stock Is 9% Down As Session Comes To An End Today - Via News Agency
via.news - May 10 at 8:07 PM
$IMGN ImmunoGen Reports Q1 Loss Per Share Of $0.17 - CML News$IMGN ImmunoGen Reports Q1 Loss Per Share Of $0.17 - CML News
cmlviz.com - May 10 at 8:07 PM
ImmunoGen (NASDAQ:IMGN) Shares Gap Down to $7.33ImmunoGen (NASDAQ:IMGN) Shares Gap Down to $7.33
americanbankingnews.com - May 10 at 3:58 PM
ImmunoGen Stock Bearish Momentum With A 8% Fall So Far Today - Via News AgencyImmunoGen Stock Bearish Momentum With A 8% Fall So Far Today - Via News Agency
via.news - May 10 at 3:06 PM
ImmunoGen EPS beats by $0.02, misses on revenue; reaffirms guidance - Seeking AlphaImmunoGen EPS beats by $0.02, misses on revenue; reaffirms guidance - Seeking Alpha
seekingalpha.com - May 10 at 3:06 PM
Immunogen: Q1 Earnings Insights - BenzingaImmunogen: Q1 Earnings Insights - Benzinga
benzinga.com - May 10 at 3:06 PM
ImmunoGen: Q1 Earnings Snapshot - New Haven RegisterImmunoGen: Q1 Earnings Snapshot - New Haven Register
nhregister.com - May 10 at 3:06 PM
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies DelayedImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed
finance.yahoo.com - May 10 at 3:06 PM
Immunogen Inc (IMGN) Q1 2021 Earnings Call TranscriptImmunogen Inc (IMGN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 10 at 3:06 PM
ImmunoGen (NASDAQ:IMGN) Releases Quarterly  Earnings Results, Beats Estimates By $0.02 EPSImmunoGen (NASDAQ:IMGN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
americanbankingnews.com - May 10 at 2:18 PM
ImmunoGen Already 5% Down, Almost One Hour Before The Market Open - Via News AgencyImmunoGen Already 5% Down, Almost One Hour Before The Market Open - Via News Agency
via.news - May 10 at 10:05 AM
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results - Business WireImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results - Business Wire
businesswire.com - May 10 at 10:05 AM
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial ResultsImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 10:05 AM
ImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue EstimatesImmunoGen (IMGN) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 10 at 10:05 AM
DateCompanyBrokerageAction
5/7/2021Travere TherapeuticsBMO Capital MarketsLower Price Target
4/12/2021Travere TherapeuticsWedbushLower Price Target
3/3/2021Travere TherapeuticsSVB LeerinkReiterated Rating
2/3/2021Travere TherapeuticsCanaccord GenuityBoost Price Target
11/23/2020Travere TherapeuticsEvercore ISIInitiated Coverage
5/7/2021Aurinia PharmaceuticalsBloom BurtonUpgrade
5/7/2021Aurinia PharmaceuticalsRoyal Bank of CanadaLower Price Target
5/7/2021Aurinia PharmaceuticalsOppenheimerReiterated Rating
1/26/2021Aurinia PharmaceuticalsCantor FitzgeraldBoost Price Target
1/25/2021Aurinia PharmaceuticalsHC WainwrightBoost Price Target
6/16/2020Aurinia PharmaceuticalsBTIG ResearchInitiated Coverage
5/5/2020Aurinia PharmaceuticalsCowenInitiated Coverage
3/29/2021Harmony BiosciencesThe Goldman Sachs GroupUpgrade
9/14/2020Harmony BiosciencesJefferies Financial GroupInitiated Coverage
9/14/2020Harmony BiosciencesPiper SandlerInitiated Coverage
2/2/2021Arcutis BiotherapeuticsTruistBoost Price Target
1/28/2021Arcutis BiotherapeuticsJonestradingInitiated Coverage
2/25/2020Arcutis BiotherapeuticsGuggenheimInitiated Coverage
5/10/2021ImmunoGenWilliam BlairReiterated Rating
9/29/2020ImmunoGenJPMorgan Chase & Co.Initiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.